| Attribute | Level 1 | Level 2 | Level 3 |
| Increase in 3-year RFS Chance of remaining cancer-free over 3 years increases X% | 4% | 8% | 12% |
| 10-year survival in metastatic melanoma | Among metastatic patients (patients whose cancer has spread), has not proven to show a survival benefit over 10 years | Among metastatic patients (patients whose cancer has spread), proven to show that 10% remain alive for at least 10 years | Among metastatic patients (patients whose cancer has spread), proven to show that 21% remain alive for at least 10 years |
| Dosing regimen | IV infusion at clinic 1 time every 3 weeks for 4 times and then 1 time every 3 months for 3 years | IV infusion at clinic 5 days a week for 1 month and then self-injection under the skin 3 times per week for 1 year | Self-injection under the skin 1 time per week for 5 years |
| Fatigue risk Chance of fatigue, not relieved by rest, limiting work and daily activities | 32% | 60% | 95% |
| Diarrhea risk Chance of diarrhea (>3 episodes per day), limiting work and daily activities | 1% | 27%
| 41%
|
| Depression risk Chance of depression, with low mood and lacking motivation, limiting work and daily activities | 1% | 40% | 59% |
| Hypophysitis risk Chance of pituitary gland inflammation, causing headaches and requiring long-term hormone therapy | 0% | 5% | 18% |